We are currently experiencing technical issues with our phone system. For immediate assistance, please email us at contact@belaydiagnostics.com. We apologize for the inconvenience.

Clinical Resources

Belay offers a growing portfolio of CSF liquid biopsy tests for CNS tumor profiling.

Explore our tests →
View our publications →
Contact our team →

News

Belay Announces Update to NCCN Guidelines to Recommend CSF-based Genomic Profiling in Biopsy Infeasible High-Grade Gliomas

June 17, 2026

Belay Diagnostics Summit™ Informed Clinical Decisions in 93% of Cases in Large Real-World CNS Study

May 6, 2026

CSF Liquid Biopsy May Help Clarify Inconclusive Leptomeningeal Disease Cases, Study Finds

April 14, 2026

Belay Diagnostics Reports 82% Clinical Impact Rate for Summit™ and Vantage™ in CNS Lymphoma Study

March 24, 2026

Belay Diagnostics Announces the Validation of Summit™ 2.0 Comprehensive Genomic Profile Assay in Cerebrospinal Fluid (CSF)

January 19, 2026

Belay Diagnostics Announces the Validation of Vantage™ Assay for Evaluation of MGMT Promoter Methylation in Cerebrospinal Fluid (CSF)

July 7, 2025

Belay Diagnostics Receives NIH Award to Advance Multi-Omic CSF Assay for Brain Cancer Diagnosis

May 9, 2025

Belay Diagnostics Announces US Commercial Launch of Summit™: Breakthrough CSF Testing for CNS Cancer Detection and Management

April 25, 2025

Belay Diagnostics Partners with GenomOncology to Support High-Performance Liquid Biopsy Test for Central Nervous System Cancer Detection

March 25, 2025